Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of
thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge …

Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …

Protease-activated receptor 4 (PAR4)(gene F2RL3) harbors a functional dimorphism,
rs773902 A/G (encoding Thr120/Ala120, respectively) and is associated with greater platelet …

Most agonists stimulate platelet Ca2+ rises via G-protein coupled receptors (GPCRs) or
ITAM-linked receptors (ILRs). Well studied are the GPCRs stimulated by the soluble agonists …

Cancer-associated thrombosis is a common first presenting sign of malignancy and is
currently the second leading cause of death in cancer patients after their malignancy …

Dual antiplatelet therapy reduces ischemic events in cardiovascular disease, but it increases
bleeding risk. Thrombin receptors PAR1 and PAR4 are drug targets, but the role of thrombin …

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a major concern for all
individuals that undergo cardiac bypass surgeries or require prolonged heparin exposure …

Protease-activated receptors (PARs) are a family of four GPCRs with a variety of cellular
functions, yet the only advanced clinical endeavours to target these receptors for therapeutic …

Background: DNA hypomethylation at the F2RL3 (F2R like thrombin or trypsin receptor 3)
locus has been associated with both smoking and atherosclerotic cardiovascular disease; …

Acute coronary syndromes (ACS) are a global cause of mortality and morbidity that affect
millions of lives worldwide. Following atherosclerotic plaque rupture, platelet activation and …